Esophageal Cancer

p53 negative expression/p53R2 expression predicts CRT outcome in ESCC

Published in Gene Therapy Weekly, April 14th, 2005

p53 negative expression and p53R2 expression predicts chemoradiation therapy outcome in esophageal squamous cell carcinoma.

According to a study from Japan, "The p53 family regulates cell- cycle arrest, triggers apoptosis or is involved in repair of DNA damage. In the present study, we analyzed the expression of some p53 family proteins and their responses to chemoradiation therapy (CRT) in cases of esophageal squamous cell carcinoma (ESCC).

"We immunohistochemically investigated the relationship between p53, p53R2, and p21 expression in biopsy specimens of untreated primary tumors and their clinical and histological responses to CRT in 62 patients...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2005-04-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry